JamesLIzanecMDAGAF

Gastroenterology • Horsham, PA

Gastrointestinal Cancer, Hepatology & Liver Transplantation, Inflammatory Bowel Disease

Janssen Scientific Affairs

Join to view full profile

Dr. Izanec is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Izanec's full profile

Already have an account?

Office
800 Ridgeview Drive
Horsham, PA 19044
Phone+1 215-325-2055

Summary

Dr. Izanec is a Medical Director in Immunology/Gastroenterology at Janssen Scientific Affairs

Education & Training

Drexel University College of Medicine/Hahnemann University HospitalFellowship, Gastroenterology, 2004 - 2007
Temple University HospitalResidency, Internal Medicine, 2001 - 2004
Weill Cornell MedicineClass of 2001

Certifications & Licensure

NJ State Medical License 2007 - 2024

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2013

Clinical Trials

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome Start of enrollment: 2005 Dec 01
Completed
Phase 2
Prevention of Recurrence of Diverticulitis Start of enrollment: 2007 Dec 06
Completed
Phase 3
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) Start of enrollment: 2008 Feb 01
Completed
Phase 3
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD) Start of enrollment: 2008 Feb 01
Completed
Phase 3
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Start of enrollment: 2009 Nov 17
Completed
Phase 3
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation Start of enrollment: 2011 Mar 01
Completed
Phase 3
Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation Start of enrollment: 2011 Apr 01
Completed
Phase 3
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain Start of enrollment: 2011 Jun 01
Terminated
Phase 3
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study Start of enrollment: 2012 Feb 01
Completed
Phase 3
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) Start of enrollment: 2012 May 29
Completed
Phase 3
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) Start of enrollment: 2012 May 29
Completed
Phase 3
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) Start of enrollment: 2013 Apr 29
Active, not recruiting
Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass Start of enrollment: 2014 Jan 01
Completed
Phase 4
Join now to see all

Publications & Presentations

PubMed

91 citations
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, rando...
Bruce E Sands, Peter M Irving, Timothy Hoops, James L Izanec, Long-Long Gao
Lancet. 2022-06-11
21 citations
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
Amanda M Johnson, Maria Barsky, Waseem Ahmed, Samantha Zullow, Jonathan Galati
The American Journal of Gastroenterology. 2023-02-01
2 citations
Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumab.
Maryia Zhdanava, Zhijie Ding, Ameur M Manceur, Ruizhi Zhao, Christopher Holiday
Current Medical Research and Opinion. 2023-09-01

Committees

Board of Directors, Cornell Club of Greater Philadelphia 2012 - Present
Board of Overseers, American Gastroenterological Association Political Action Committee 2011 - Present